<rst>
<header>
	<relations>
			<rel name="means" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="background" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="purpose" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="sequence" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">7. Involvement of the Apelin System in the Pathogenesis of Liver Fibrosis</segment>
<segment id="2" parent="1002" relname="contrast">The apelin system has certain therapeutic abilities ,</segment>
<segment id="3" parent="1003" relname="span">but it may also play a role in disease</segment>
<segment id="4" parent="3" relname="elaboration">depending on the cellular and molecular milieu .</segment>
<segment id="5" parent="1004" relname="joint">A clear example of this is the role of apelin in tissue fibrosis .</segment>
<segment id="6" parent="1004" relname="joint">Apelin displays anti-fibrotic actions counteracting AII in models of cardiac fibrosis and renal fibrosis .</segment>
<segment id="7" parent="1007" relname="span">In contrast , the scenario and role of the apelin system are completely different in liver disease .</segment>
<segment id="8" parent="1008" relname="span">Apelin is a hepatic pro-fibrotic agent , in part by mediating some of the fibrogenic effects</segment>
<segment id="9" parent="1009" relname="span">triggered by AII and ET-1 in the activation of HSC</segment>
<segment id="10" parent="9" relname="elaboration">occurring in liver fibrosis .</segment>
<segment id="11" parent="1012" relname="span">These outcomes highlight the intriguing difference between myofibroblastic-cell types in liver compared to myofibroblasts in heart , kidney , or skin</segment>
<segment id="12" parent="11" relname="elaboration">in which apelin acts</segment>
<segment id="13" parent="1012" relname="means">by decreasing myofibroblast accumulation and activity .</segment>
<segment id="14" parent="1014" relname="span">In vitro , apelin has also demonstrated a significant potential</segment>
<segment id="15" parent="14" relname="purpose">to promote liver fibrosis .</segment>
<segment id="16" parent="1016" relname="span">It acts directly on LX-2 cells</segment>
<segment id="17" parent="1018" relname="span">( a cell line</segment>
<segment id="18" parent="17" relname="elaboration">used as a reliable in vitro model of HSC )</segment>
<segment id="19" parent="1017" relname="same_unit">through Erk signalling ,</segment>
<segment id="20" parent="1020" relname="span">stimulating cell survival and the synthesis of PDGF-β receptor and collagen-I in these cells .</segment>
<segment id="21" parent="1021" relname="joint">In turn , PDGF-β and LPS can stimulate the expression of APJ , expanding and perpetuating HSC activation .</segment>
<segment id="22" parent="1022" relname="sequence">Therefore , apelin may , in theory , induce HSC to a pro-fibrogenic profile</segment>
<segment id="23" parent="1022" relname="sequence">and prolong its stimulation autocrinally during all stages of liver fibrosis in chronic liver disease (</segment>
<segment id="24" parent="1024" relname="preparation">Figure 6</segment>
<segment id="25" parent="1025" relname="preparation">) .</segment>
<segment id="26" parent="1027" relname="attribution">In fact , some data have revealed</segment>
<segment id="27" parent="1029" relname="span">that the inhibition of APJ</segment>
<segment id="28" parent="1030" relname="span">using F13A</segment>
<segment id="29" parent="28" relname="elaboration">( an APJ antagonist )</segment>
<segment id="30" parent="1028" relname="same_unit">prevents fibrosis progression in rats under a non-discontinued fibrosis induction program</segment>
<segment id="31" parent="1028" relname="means">using CCl4 .</segment>
<segment id="32" parent="1031" relname="joint">Several investigations have uncovered the close and integrated relationship between pathological angiogenesis and fibrosis .</segment>
<segment id="33" parent="34" relname="circumstance">As mentioned above ,</segment>
<segment id="34" parent="1033" relname="span">apelin is a powerful angiogenic agent through the activation of endothelial APJ and different downstream signalling pathways .</segment>
<segment id="35" parent="1034" relname="joint">Two reports have associated the inhibition of APJ with a reduction in angiogenesis and with a concomitant drop in fibrosis in CH and fibrotic rats .</segment>
<segment id="36" parent="1036" relname="span">Although a direct relationship was not established between the two phenomena ,</segment>
<segment id="37" parent="1037" relname="span">there are evidence</segment>
<segment id="38" parent="1039" relname="attribution">pointing out</segment>
<segment id="39" parent="1040" relname="span">that APJ activation by apelin stimulates the expression of a well-known pro-angiogenic factor , angiopoietin-1</segment>
<segment id="40" parent="1041" relname="span">( from the angiopoietin family</segment>
<segment id="41" parent="40" relname="elaboration">involved in pathological angiogenesis in chronic liver disease )</segment>
<segment id="42" parent="1039" relname="same_unit">in LX-2 cells .</segment>
<segment id="43" parent="1044" relname="attribution">This suggests</segment>
<segment id="44" parent="1044" relname="span">that fibrogenic cells such as HSC may participate in hepatic angiogenesis</segment>
<segment id="45" parent="44" relname="means">by secreting angiogenic factors such as angiopoietin 1 .</segment>
<segment id="46" parent="1046" relname="span">Indeed , the inhibition of HSC-secreted angiopietin-1 has shown to drastically reduce pathological angiogenesis and liver fibrosis</segment>
<segment id="47" parent="46" relname="elaboration">induced in mice by either CCl4 or BDL .</segment>
<segment id="48" parent="1048" relname="span">Aside from HSC , hepatocytes have also been related to contribute to both phenomena , pathological angiogenesis and liver fibrosis ,</segment>
<segment id="49" parent="48" relname="means">by releasing pro-angiogenic and pro-fibrogenic factors .</segment>
<segment id="50" parent="1051" relname="attribution">There is a growing belief</segment>
<segment id="51" parent="1051" relname="span">that local hypoxia is the link interconnecting both pathological angiogenesis and liver fibrogenesis ,</segment>
<segment id="52" parent="51" relname="elaboration">orchestrating the harmonic and coordinated activation of HSC , hepatocytes and other hepatic cells .</segment>
<segment id="53" parent="1053" relname="span">Detection of hypoxic areas is a common trait at any stage of chronic liver disease ,</segment>
<segment id="54" parent="1054" relname="span">expanding progressively from early injury to the development of cirrhosis . ,</segment>
<segment id="55" parent="1056" relname="span">Through the action of hypoxia-inducible factors</segment>
<segment id="56" parent="55" relname="elaboration">( HIF ) ,</segment>
<segment id="57" parent="1055" relname="same_unit">hepatic hypoxia up-regulates the expression of a wide array of growth factors and mediators of liver repair and angiogenesis .</segment>
<segment id="58" parent="1059" relname="span">However , pathological angiogenesis can be inefficient due to the immaturity and permeability of vascular endothelial growth factor</segment>
<segment id="59" parent="58" relname="elaboration">( VEGF)-induced new vessels</segment>
<segment id="60" parent="1058" relname="joint">and , consequently , the liver may be unable to reduce hypoxia .</segment>
<segment id="61" parent="1062" relname="span">Hypoxia up-regulates in vitro the expression of APJ in LX-2</segment>
<segment id="62" parent="61" relname="elaboration">( HSC )</segment>
<segment id="63" parent="1063" relname="span">and in HepG2</segment>
<segment id="64" parent="63" relname="elaboration">( hepatocytes ) .</segment>
<segment id="65" parent="1064" relname="joint">Interestingly , the pro-inflammatory and pro-fibrogenic agents TNF-α and AII also induce the expression of APJ in HepG2 cells .</segment>
<segment id="66" parent="1066" relname="span">APJ activation in HepG2 cells triggers the expression of VEGF-A and PDGF-β , factors</segment>
<segment id="67" parent="66" relname="elaboration">that in turn may promote angiogenesis and activation of HSC and , consequently , liver fibrosis .</segment>
<segment id="68" parent="1068" relname="span">According to these data , hypoxia , inflammation and pro-fibrogenic factors up-regulate APJ in HSC and hepatocytes ,</segment>
<segment id="69" parent="1070" relname="span">which can release different pro-angiogenic and pro-fibrogenic factors such as apelin</segment>
<segment id="70" parent="69" relname="elaboration">( from activated HSC )</segment>
<segment id="71" parent="1072" relname="span">together</segment>
<segment id="72" parent="71" relname="purpose">to perpetuate fibrosis</segment>
<segment id="73" parent="1072" relname="circumstance">while injury and these stimuli remain .</segment>
<segment id="74" parent="1074" relname="span">In vivo , APJ is upregulated preferentially in hepatocytes and HSC ,</segment>
<segment id="75" parent="1075" relname="span">while apelin levels are increased and localized in HSC in cirrhotic rats and in patients with liver cirrhosis</segment>
<segment id="76" parent="75" relname="elaboration">caused by hepatitis C virus or ethanol .</segment>
<segment id="77" parent="1076" relname="span">High apelin levels and liver damage have also been observed in human non-alcoholic fatty liver disease .</segment>
<segment id="78" parent="79" relname="attribution">A contemporary clinical investigation revealed</segment>
<segment id="79" parent="1078" relname="span">that circulating apelin levels are associated with histological and hemodynamic features of chronic liver disease ,</segment>
<segment id="80" parent="1079" relname="span">but more clinical studies are needed</segment>
<segment id="81" parent="80" relname="purpose">to confirm the major relevance of apelin system in human liver fibrosis .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="multinuc" parent="1004" relname="background"/>
<group id="1003" type="span" parent="1002" relname="contrast"/>
<group id="1004" type="multinuc" parent="1001" relname="span"/>
<group id="1006" type="span" parent="1004" relname="joint"/>
<group id="1007" type="span" parent="1006" relname="span"/>
<group id="1008" type="span" parent="7" relname="elaboration"/>
<group id="1009" type="span" parent="8" relname="elaboration"/>
<group id="1010" type="multinuc" parent="1007" relname="elaboration"/>
<group id="1011" type="span" parent="1010" relname="sequence"/>
<group id="1012" type="span" parent="1011" relname="span"/>
<group id="1013" type="multinuc" parent="1010" relname="sequence"/>
<group id="1014" type="span" parent="1013" relname="sequence"/>
<group id="1015" type="multinuc" parent="1013" relname="sequence"/>
<group id="1016" type="span" parent="1015" relname="joint"/>
<group id="1017" type="multinuc" parent="16" relname="elaboration"/>
<group id="1018" type="span" parent="1017" relname="same_unit"/>
<group id="1019" type="multinuc" parent="1015" relname="joint"/>
<group id="1020" type="span" parent="1019" relname="joint"/>
<group id="1021" type="multinuc" parent="20" relname="elaboration"/>
<group id="1022" type="multinuc" parent="1021" relname="joint"/>
<group id="1023" type="span" parent="1019" relname="joint"/>
<group id="1024" type="span" parent="1023" relname="span"/>
<group id="1025" type="multinuc" parent="1024" relname="span"/>
<group id="1026" type="span" parent="1025" relname="joint"/>
<group id="1027" type="span" parent="1026" relname="span"/>
<group id="1028" type="multinuc" parent="1027" relname="span"/>
<group id="1029" type="span" parent="1028" relname="same_unit"/>
<group id="1030" type="span" parent="27" relname="means"/>
<group id="1031" type="multinuc" parent="1025" relname="joint"/>
<group id="1032" type="multinuc" parent="1031" relname="joint"/>
<group id="1033" type="span" parent="1032" relname="joint"/>
<group id="1034" type="multinuc" parent="1032" relname="joint"/>
<group id="1035" type="multinuc" parent="1034" relname="joint"/>
<group id="1036" type="span" parent="1035" relname="joint"/>
<group id="1037" type="span" parent="36" relname="elaboration"/>
<group id="1038" type="span" parent="37" relname="elaboration"/>
<group id="1039" type="multinuc" parent="1038" relname="span"/>
<group id="1040" type="span" parent="1039" relname="same_unit"/>
<group id="1041" type="span" parent="39" relname="elaboration"/>
<group id="1042" type="multinuc" parent="1035" relname="joint"/>
<group id="1043" type="span" parent="1042" relname="joint"/>
<group id="1044" type="span" parent="1043" relname="span"/>
<group id="1045" type="multinuc" parent="1042" relname="joint"/>
<group id="1046" type="span" parent="1045" relname="joint"/>
<group id="1047" type="multinuc" parent="1045" relname="joint"/>
<group id="1048" type="span" parent="1047" relname="joint"/>
<group id="1049" type="multinuc" parent="1047" relname="joint"/>
<group id="1050" type="span" parent="1049" relname="joint"/>
<group id="1051" type="span" parent="1050" relname="span"/>
<group id="1052" type="multinuc" parent="1049" relname="joint"/>
<group id="1053" type="span" parent="1052" relname="joint"/>
<group id="1054" type="span" parent="53" relname="elaboration"/>
<group id="1055" type="multinuc" parent="54" relname="purpose"/>
<group id="1056" type="span" parent="1055" relname="same_unit"/>
<group id="1057" type="multinuc" parent="1052" relname="joint"/>
<group id="1058" type="multinuc" parent="1057" relname="joint"/>
<group id="1059" type="span" parent="1058" relname="joint"/>
<group id="1060" type="multinuc" parent="1057" relname="joint"/>
<group id="1061" type="multinuc" parent="1060" relname="joint"/>
<group id="1062" type="span" parent="1061" relname="same_unit"/>
<group id="1063" type="span" parent="1061" relname="same_unit"/>
<group id="1064" type="multinuc" parent="1060" relname="joint"/>
<group id="1065" type="multinuc" parent="1064" relname="joint"/>
<group id="1066" type="span" parent="1065" relname="joint"/>
<group id="1067" type="multinuc" parent="1065" relname="joint"/>
<group id="1068" type="span" parent="1067" relname="joint"/>
<group id="1069" type="multinuc" parent="68" relname="elaboration"/>
<group id="1070" type="span" parent="1069" relname="same_unit"/>
<group id="1071" type="span" parent="1069" relname="same_unit"/>
<group id="1072" type="span" parent="1071" relname="span"/>
<group id="1073" type="multinuc" parent="1067" relname="joint"/>
<group id="1074" type="span" parent="1073" relname="joint"/>
<group id="1075" type="span" parent="74" relname="circumstance"/>
<group id="1076" type="span" parent="1073" relname="joint"/>
<group id="1077" type="multinuc" parent="77" relname="elaboration"/>
<group id="1078" type="span" parent="1077" relname="joint"/>
<group id="1079" type="span" parent="1077" relname="joint"/>
	</body>
</rst>
